Welcome to our dedicated page for Anika Therapeutics SEC filings (Ticker: ANIK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anika Therapeutics, Inc. (NASDAQ: ANIK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Anika uses these filings to report its financial results, clinical and regulatory milestones, governance decisions, and equity compensation arrangements as it advances osteoarthritis pain management and regenerative orthopedic solutions based on hyaluronic acid and implant technologies.
Investors can review Form 8-K current reports in which Anika furnishes press releases on quarterly financial results, such as those for the second and third quarters of 2025, and discusses non-GAAP measures like Adjusted EBITDA and adjusted net income from continuing operations. Other 8-K filings describe material events including the filing of the third and final Premarket Approval (PMA) module for the Hyalofast cartilage repair scaffold, topline results from the U.S. pivotal FastTRACK Phase III study, and amendments to the company’s 2017 Omnibus Incentive Plan approved by stockholders.
Through its proxy-related disclosures and meeting results, Anika reports on governance and compensation matters, including director elections, advisory votes on executive compensation, and increases to share reserves under its omnibus incentive plan. Additional filings document inducement equity grants made under a separate inducement plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing detail on stock option terms and vesting conditions for newly hired employees.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of earnings releases, clinical and regulatory updates, plan amendments, and other material events. Users can track new 8-Ks and other SEC forms as they are posted to EDGAR, and use the summaries to focus on the sections most relevant to Anika’s OA pain management and regenerative solutions strategy, capital structure, and corporate governance.
Anika Therapeutics President and CEO Stephen D. Griffin, who is also a director, reported new equity awards effective February 1, 2026. He was granted 310,207 stock appreciation rights with an exercise price of
Both the stock appreciation rights and RSUs were awarded at no cash cost to him and are granted under Anika’s 2017 Omnibus Incentive Plan. They vest in three equal annual installments, beginning on February 1, 2027, conditioned on his continued service.
Following these awards, Griffin directly holds 10,671 shares of Anika common stock, which includes 800 shares acquired on November 14, 2025 through the company’s Employee Stock Purchase Plan. The stock appreciation rights may be settled in cash, shares, or a combination, and each RSU represents the right to one share or the cash equivalent on vesting.
Caligan Partners and David Johnson report their current stake in Anika Therapeutics, Inc. on Amendment No. 5 to Schedule 13D. They report beneficial ownership of 1,435,130 shares of Anika common stock, representing 9.95% of the outstanding class, with shared voting and dispositive power over all these shares.
The filing also describes additional economic exposure through cash-settled swap agreements. Caligan-related funds hold derivative agreements referencing 623,621 Anika shares, providing economic results comparable to ownership for about 4.3% of the common stock. These swaps do not give voting or dispositive power, and the reporting persons explicitly disclaim beneficial ownership of the referenced shares.
Anika Therapeutics, Inc. filed a report detailing a leadership transition while reaffirming its guidance for the year ended December 31, 2025, including expectations that Adjusted EBITDA margin will range from positive 3% to negative 3% of revenue.
The company announced that President and Chief Executive Officer Cheryl R. Blanchard will step down from the CEO role effective February 1, 2026, moving to Executive Chair for twelve months, then Special Advisor for six months, and remaining an employee through January 31, 2028. Under a transition agreement, she will receive cash severance equal to 18 months of base salary paid over 24 months and continued eligibility for benefits and equity vesting during her service.
Steve Griffin, currently Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer effective February 1, 2026 and will also join the Board as a Class III director. His new employment agreement provides a $690,000 annual base salary, a target annual bonus equal to 75% of base salary starting in 2026, and equity awards with a target grant date fair value of $2,450,000 in restricted stock units and stock appreciation rights vesting over three years. Director Susan N. Vogt will resign from the Board effective February 1, 2026 with no reported disagreements, and the company has entered into indemnification agreements with each director.
Anika Therapeutics, Inc.12/31/2025. The group reports beneficial ownership of 168,400 shares of common stock, representing 1.2% of the outstanding class.
The filing shows no sole voting or dispositive power, with all voting and dispositive authority reported as shared. Each reporting person states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Anika. They also disclaim beneficial ownership of the shares except to the extent of any pecuniary interest.
Anika Therapeutics, Inc. registered 475,000 additional shares of common stock on Form S-8 for issuance under its 2017 Omnibus Incentive Plan. The increase in the plan reserve was approved by the Board and subsequently approved by stockholders on June 20, 2025.
The newly registered shares are the same class as those covered by prior S-8 registrations for this plan, allowing continued grants under the company’s equity compensation program.
Anika Therapeutics (ANIK) reported Q3 2025 results. Revenue was $27.8M with gross margin at 56%, producing a net loss of $2.3M and a loss from continuing operations of $3.2M. Adjusted EBITDA was $0.9M. For the nine months, revenue totaled $82.2M with gross margin at 54% and a net loss of $11.2M.
Channel mix shifted: OEM revenue declined 20% in Q3, driven by lower pricing from J&J MedTech, while Commercial Channel grew 22%. J&J MedTech represented 51% of Q3 revenue. Cash and cash equivalents were $58.0M, and no repurchases occurred in Q3 after completing the first $15.0M tranche of the $40.0M program by June 2025.
Strategically, Anika completed the sales of Arthrosurface and Parcus Medical and sharpened focus on OA Pain Management and Regenerative Solutions. J&J MedTech extended exclusive U.S. rights to market Monovisc through December 2031. For Hyalofast, the U.S. pivotal study did not meet co-primary endpoints, but the final PMA module was submitted on October 31, 2025, supported by improvements on key secondary endpoints.
Anika Therapeutics (ANIK) filed an 8‑K noting it furnished a press release with its financial results for the third quarter ended September 30, 2025. The company states this information is being furnished, not filed, under the Exchange Act. The earnings press release is attached as Exhibit 99.1.
Anika also announced a regulatory milestone for Hyalofast. The company filed the third and final module of its Premarket Approval application for Hyalofast, a resorbable, hyaluronic acid‑based scaffold used with autologous bone marrow aspirate concentrate to treat articular cartilage defects in the knee, and reported results from its U.S. pivotal Phase III FastTRACK trial evaluating Hyalofast. This update is provided via a separate press release attached as Exhibit 99.2.
On 30 Jul 2025, Anika Therapeutics (ANIK) filed a Form 8-K (Item 7.01) to furnish a press release (Exhibit 99.1) announcing top-line results from its U.S. pivotal FastTRACK Phase III study of the Hyalofast cartilage-repair scaffold and providing a program update. No financial figures, efficacy data, or regulatory timelines are included in the filing itself; those details reside in the furnished press release, which is not reproduced here. The information is deemed “furnished,” not “filed,” so it is excluded from Exchange Act liability and will not be automatically incorporated into future SEC filings. Apart from the exhibit list, the 8-K contains no additional disclosures under Items 1–6, and there are no financial statements attached.
FAQ
What is the current stock price of Anika Therapeutics (ANIK)?
What is the market cap of Anika Therapeutics (ANIK)?
